The GLP-1 File

What Is GLP-1?

Glucagon-like peptide-1 (GLP-1) is a 30-amino-acid incretin hormone released by intestinal L-cells in response to nutrient intake. It is cleaved from the proglucagon gene product, the same precursor that produces glucagon and GLP-2. Postprandial GLP-1 secretion peaks within 15 to 30 minutes of eating and falls back to baseline within an hour.

Endogenous GLP-1 has a half-life of roughly 2 minutes. The native peptide is rapidly degraded by dipeptidyl peptidase-4 (DPP-4) at the second N-terminal amino acid. This is why DPP-4 inhibitors (sitagliptin, linagliptin) work as a separate diabetes drug class: they prolong endogenous GLP-1 by blocking its degradation, though to a much smaller effect than receptor agonism.

The receptor for GLP-1 (GLP-1R) is a class B G-protein-coupled receptor expressed on pancreatic beta cells, gastric smooth muscle, cardiac myocytes, vagal afferents, and several hypothalamic and brainstem nuclei. The distribution of the receptor is what gives the class its broad effects beyond glycaemic control. Receptor agonism in the arcuate nucleus and area postrema is the basis of the appetite-suppressing and nausea-inducing effects. Receptor agonism in cardiac and vascular tissue is the basis of the cardiovascular outcomes seen in SELECT and similar trials.

A GLP-1 receptor agonist is any molecule that binds and activates GLP-1R. The class includes peptide agonists (liraglutide, semaglutide, tirzepatide, retatrutide), oral non-peptide small molecules (orforglipron, in late-stage trials), and antibody-conjugated agonists (MariTide). The biological effect is driven by receptor binding affinity, plasma half-life, and tissue distribution. Engineering for half-life through fatty acid conjugation (semaglutide, liraglutide) or Fc-fusion (dulaglutide, retatrutide) is what enables once-weekly dosing.

The historical arc is worth noting. Exendin-4, the active component of exenatide, was isolated from the venom of the Gila monster (Heloderma suspectum) by John Eng at the Bronx VA Medical Center in 1992. Exendin-4 shares 53% sequence identity with native human GLP-1 but resists DPP-4 cleavage, giving it a much longer half-life. Exenatide became the first approved GLP-1 receptor agonist in 2005, dosed twice daily. Liraglutide followed in 2010 with the addition of a fatty acid side chain that bound albumin, extending half-life to 13 hours. Semaglutide, approved in 2017, used a longer fatty acid chain plus amino acid substitutions to achieve a 7-day half-life. Each engineering advance was incremental, but together they took the class from twice-daily injections producing modest glycaemic improvement to once-weekly injections producing transformative weight loss.

How GLP-1 Agonists Work

The mechanism is multi-organ. GLP-1 agonists hit the pancreas, gut, brain, and cardiovascular system simultaneously, which is why the clinical picture spans glycaemic control, weight loss, and reduced cardiovascular events from a single drug.

• Pancreas (glucose-dependent insulin)GLP-1R agonism stimulates insulin secretion from beta cells only when blood glucose is elevated. The glucose dependency is critical: insulin release rises only at hyperglycaemia, which is why the class carries low intrinsic hypoglycaemia risk in non-diabetic patients. GLP-1 also suppresses glucagon from alpha cells, reducing hepatic glucose output. Net effect: HbA1c reductions of 1.0 to 1.8 percentage points in T2D trials.
• Stomach (delayed gastric emptying)GLP-1 agonism slows gastric emptying. Food remains in the stomach longer, blunting the postprandial glucose excursion and prolonging satiety. The slowed emptying is also responsible for much of the class's side effect profile: nausea, vomiting, and early satiety affect 20 to 50% of patients during dose titration.
• Brain (hypothalamic appetite suppression)The hypothalamic arcuate nucleus and area postrema express GLP-1 receptors. Agonism activates POMC neurons (anorexigenic) and inhibits NPY/AgRP neurons (orexigenic), producing sustained reductions in appetite and food preference. fMRI studies show reduced reward-system activation in response to high-calorie food cues. This is the neural substrate of the 'food noise' reduction patients describe.
• Cardiovascular (direct vascular effects)GLP-1 receptors are expressed on cardiac myocytes and vascular endothelium. Agonism produces modest blood pressure reduction, lipid improvements, and direct anti-inflammatory effects. SELECT confirmed a 20% MACE reduction over a mean 39.8 months in patients with established cardiovascular disease and BMI ≥27.

The full mechanistic picture, including the GIP and glucagon arms relevant to dual and triple agonists, is covered in the dedicated how GLP-1 agonists work article.

The GLP-1 Agonist Class

The class spans five approved compounds plus retatrutide in late Phase III, with orforglipron in Phase III as the first oral non-peptide candidate. The progression maps onto receptor coverage: GLP-1 alone, then GLP-1 plus GIP, then GLP-1 plus GIP plus glucagon. Each step adds approximately 5 to 7 percentage points of weight loss over the previous one.

For the full side-by-side including dose ranges, half-life, brand names, and cost in major markets, see the GLP-1 comparison chart for 2026.

Weight Loss: What the Data Shows

Three points are worth holding in mind when reading trial data across the class. First, the comparator matters. STEP 1 compared semaglutide 2.4mg against placebo in patients with obesity but without diabetes. SURMOUNT-1 used the same design for tirzepatide. The headline efficacy figures are not directly comparable across compounds without correcting for trial design, baseline BMI, and duration. SURMOUNT-5 was the first true head-to-head of semaglutide vs tirzepatide and confirmed the efficacy ranking suggested by indirect comparison.

Trial Headlines

• Liraglutide 3.0mg8.0% weight loss at 56 weeks. SCALE Obesity and Prediabetes (Pi-Sunyer et al., NEJM 2015, PMID 26132939). The first GLP-1 agonist to secure an obesity indication.
• Semaglutide 2.4mg14.9% weight loss at 68 weeks. STEP 1 (Wilding et al., NEJM 2021, PMID 33567185). The trial that broke the 10% ceiling and reset class expectations.
• Tirzepatide 15mg22.5% weight loss at 72 weeks. SURMOUNT-1 (Jastreboff et al., NEJM 2022, PMID 35658024). First dual GLP-1/GIP agonist; first time the 20% line was crossed.
• SURMOUNT-5 head-to-headTirzepatide 20.2% vs semaglutide 13.7% at 72 weeks (Aronne et al., NEJM 2025). The first direct comparison of the two leading approved agents.
• Retatrutide 12mg28.7% weight loss at 68 weeks. TRIUMPH-4 (Phase III, December 2025 data). The strongest weight loss ever recorded in a randomised obesity trial.

The Real-World Discount

Trial populations were typically high-BMI (mean BMI 35 to 40) and excluded patients with significant comorbidities or polypharmacy. Real-world populations include more variability in baseline BMI, more diabetes, more medication interactions, and more variable adherence. The 60 to 75% real-world adherence rule is a useful heuristic across the class. Real-world weight loss runs 60 to 75% of trial figures.

Cardiovascular Benefit, Beyond Weight

The GLP-1 class has produced cardiovascular outcomes data well beyond what FDA approval originally required. The 2008 FDA cardiovascular safety guidance for diabetes drugs was meant to ensure new drugs did not increase risk. The class has now produced multiple trials demonstrating cardiovascular benefit: LEADER (liraglutide, 2016), SUSTAIN-6 (semaglutide diabetes, 2016), REWIND (dulaglutide, 2019), and SELECT (semaglutide in obesity without diabetes, 2023). The transition from a safety requirement to an efficacy indication has reshaped how the class is prescribed in patients with established cardiovascular disease.

GLP-1 vs GIP

GIP (glucose-dependent insulinotropic polypeptide) is the second incretin hormone. It is released by K-cells in the duodenum and jejunum, while GLP-1 is released by L-cells primarily in the ileum and colon. GIP and GLP-1 together account for the incretin effect: the observation that oral glucose produces a larger insulin response than intravenous glucose at matched plasma glucose levels.

GIP receptor (GIPR) biology was historically considered less interesting than GLP-1R. GIP appeared to have minimal effect on appetite and was thought to be ineffective in type 2 diabetes (GIP signalling is reduced in diabetic patients). Tirzepatide changed that view. Combined GLP-1R and GIPR agonism produced weight loss exceeding what semaglutide could achieve at any tolerable dose.

The deep dive on receptor biology, GIP knockout mouse data, and the unresolved question of agonism versus antagonism is in the GLP-1 vs GIP comparison.

Triple vs Dual Agonism

Adding glucagon receptor agonism to GLP-1 plus GIP introduces a third mechanism: increased energy expenditure. GLP-1 and GIP together reduce energy intake. Glucagon raises energy expenditure through hepatic glucose output, lipolysis, and brown adipose tissue activation. The combined effect is a larger negative energy balance than dual agonism can achieve.

The risk with glucagon agonism is hyperglycaemia. Glucagon raises blood glucose by definition. Retatrutide solves this by combining glucagon agonism with strong GLP-1 plus GIP agonism, so the insulinotropic effect of the incretin component dominates. TRIUMPH-2 data in type 2 diabetes confirmed glycaemic improvement despite the glucagon component, with HbA1c reductions of around 2.0 percentage points.

The 28.7% figure from TRIUMPH-4 is roughly 6 percentage points above tirzepatide's 22.5% in SURMOUNT-1 (with differences in trial population and duration noted). That gap is consistent with the pattern of approximately 5 to 7 percentage points added per receptor target. Whether this pattern continues with quad agonists (GLP-1, GIP, glucagon, plus a fourth target like amylin or PYY) is the open question for the next decade.

Full analysis, the trial data on glucagon mono-agonism, and the question of whether a quad agonist makes biological sense are covered in the triple vs dual agonism explainer. For the head-to-head specifically on retatrutide vs the dual agonist class, see retatrutide vs tirzepatide.

Safety Profile

After almost two decades of post-marketing data, the safety picture is reasonably settled. The common side effects are gastrointestinal: nausea, vomiting, diarrhoea, constipation. These affect 20 to 50% of patients during dose titration and typically resolve within 4 to 8 weeks of dose stabilisation. Slow dose escalation reduces incidence and severity.

• PancreatitisKnown but rare signal. Background incidence in T2D is elevated regardless of treatment. Meta-analyses have not shown significant increases over comparators, though FDA labels carry warnings.
• Gallbladder eventsCholecystitis and cholelithiasis are more common with GLP-1 agonists than placebo, particularly with rapid weight loss. Mechanism is partly the weight loss itself, partly direct GI effects.
• Thyroid C-cell signalTumours observed in rodent toxicology studies of liraglutide and exenatide, leading to boxed warnings about medullary thyroid carcinoma and contraindications in MTC or MEN 2. Human data over 15 years has not confirmed an increased risk.
• Cardiovascular outcomeNet positive across the class. SELECT (semaglutide), LEADER (liraglutide), REWIND (dulaglutide), and SUSTAIN-6 all reported MACE reductions in high-risk populations. The class moved from a CV safety requirement to a CV benefit indication within a decade.
• Suicidal ideationEMA and FDA review in 2023 to 2024 did not find a causal link. Monitoring continues. Trial populations report rates similar to placebo.
• Dysesthesia (retatrutide-specific)Reported in 20.9% of retatrutide 12mg patients in TRIUMPH-4. The first time this signal has emerged in the class. Not seen with semaglutide or tirzepatide. Linked to glucagon receptor activity.
• Lean mass lossApproximately 40% of total weight loss came from lean mass in DXA substudies of STEP 1, with 60% from fat. Proportions are similar to bariatric surgery and dietary weight loss at matched rate. Trial fracture rates have not been elevated, but most trial populations were younger than the typical osteoporosis-risk demographic.

The full safety synthesis, including comparisons of dose-titration tolerability across compounds, is in the GLP-1 safety profile explainer.

Natural GLP-1 Boosters

The endogenous GLP-1 axis is sensitive to diet composition. Reliable stimulators of postprandial GLP-1 secretion include protein-rich meals (especially whey and casein, with a 30 to 50% rise in postprandial GLP-1), soluble fibre (oats, legumes, psyllium, with secondary effects via short-chain fatty acid production by gut microbiota), monounsaturated fats (olive oil, avocado), and fermented foods (some evidence for kimchi, kefir, and yoghurt). Bitter compounds (gentian, hops, coffee) acutely raise GLP-1 via taste receptor signalling in the gut.

The honest framing: these effects are real but modest. A protein-rich meal might double postprandial GLP-1 from baseline. A weekly semaglutide injection produces sustained plasma agonist levels roughly 1,000 times higher than physiological postprandial peaks. The clinical effect sizes match: diet alone produces 3 to 5% weight loss in well-conducted trials over a year. GLP-1 agonists produce 8 to 28% over similar timeframes.

For most readers the practical takeaway is that diet composition matters for endogenous GLP-1 in the same way that walking matters for cardiovascular health: it is genuinely beneficial and worth doing, but it does not substitute for the pharmacological intervention when the latter is indicated. The full evidence rundown is in the natural GLP-1 boosters guide.

Practical Considerations

Dosing and Titration

Every approved GLP-1 agonist requires gradual dose titration, with increases every 4 weeks until the target dose is reached. Semaglutide 2.4mg starts at 0.25mg and steps through 0.5, 1.0, 1.7 to 2.4. Tirzepatide steps through 2.5, 5, 7.5, 10, 12.5, 15. Skipping titration steps increases GI side effect severity and discontinuation risk.

Cost and Access

• Wegovy 2.4mg~$1,350 / month US list price
• Zepbound 5–15mg~$1,060 / month US list price
• Ozempic 2.0mg~$1,000 / month US list price
• Mounjaro 15mg~$1,070 / month US list price
• UK / EU pricesSubstantially lower under negotiated reimbursement

Insurance coverage for obesity (as opposed to diabetes) varies widely and is the dominant access barrier in the US. The same structural barriers will apply to retatrutide post-approval.

Compounded Versions

Compounded semaglutide and tirzepatide flooded the US market during the 2022 to 2024 shortages. The FDA designated both as resolved shortages in late 2024 and early 2025, removing the legal basis for routine 503A compounding. Specific patient-need exceptions remain. The compounding pharmacy market has shifted toward research peptides and peptide blends, which sit in a different regulatory category. Quality and purity vary widely; independent third-party testing is the only way to verify what is in any compounded product.

Discontinuation and Weight Regain

Stopping a GLP-1 agonist results in significant weight regain. The STEP 1 extension trial showed that participants who stopped semaglutide regained roughly two-thirds of their lost weight within one year. This is consistent with framing obesity as a chronic disease requiring ongoing treatment, similar to hypertension or hyperlipidaemia. Maintenance dosing rather than discontinuation is the current clinical norm for patients who tolerate the drug.

The 2026 Pipeline

The next generation of incretin therapies is in late-stage trials. Multiple readouts will arrive through 2026 and 2027, and the efficacy ceiling continues to climb.

For the head-to-head on the two leading approved compounds, see semaglutide vs tirzepatide. For the deep dive on the leading Phase III candidate, see the Retatrutide File.

Mono vs Dual vs Triple Agonism

The summary view of the class progression. Each receptor target adds clinically meaningful weight loss but introduces additional complexity in the safety profile.

What We Don't Yet Know

• Whether GIPR agonism or antagonism is the better approach

  Tirzepatide (GIPR agonist) and MariTide (GIPR antagonist) both work. The biology is unsettled. MariTide Phase III readouts in 2027 should help.

• Long-term safety at high doses

  Most safety data is at lower doses or shorter durations. Decades-long maintenance dosing on retatrutide-class drugs is uncharted.

• Cardiovascular outcomes for tirzepatide and retatrutide

  SURMOUNT-MMO (tirzepatide) and TRIUMPH-3 (retatrutide) are ongoing. Whether the class CV benefit extends to dual and triple agonists is not yet confirmed in pivotal trials.

• Whether the efficacy ceiling continues to climb

  Quad agonists (GLP-1 + GIP + glucagon + amylin or PYY) are in preclinical work. Whether adding a fourth target adds weight loss or hits diminishing returns is open.

• Bone density and fracture risk in older patients

  Trial populations skew younger than the typical osteoporosis-risk demographic. Long-term effects of substantial lean mass loss in older adults remain under-characterised.

• Effects in adolescents and pregnancy

  Adolescent indications are emerging (semaglutide approved for ≥12y in some markets). Pregnancy data is limited and the class is generally avoided.

• Optimal maintenance dose strategy

  Whether patients can step down from peak dose to a maintenance dose without losing efficacy. Trial protocols use peak dose throughout; real-world dose-reduction data is limited.

• Effects on neurodegenerative and addiction outcomes

  GLP-1 agonism is being trialled in Alzheimer's disease (evoke trial), alcohol use disorder, and other addiction phenotypes. Early signals are positive but preliminary.

Frequently Asked Questions